GeneDx (NASDAQ:WGS) Announces Earnings Results, Beats Estimates By $0.66 EPS

GeneDx (NASDAQ:WGS - Get Free Report) issued its earnings results on Tuesday. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.66, Zacks reports. The company had revenue of $95.64 million for the quarter, compared to analysts' expectations of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. GeneDx updated its FY 2025 guidance to EPS.

GeneDx Stock Performance

GeneDx stock traded down $5.75 during trading hours on Friday, hitting $95.83. The company had a trading volume of 1,151,027 shares, compared to its average volume of 1,255,238. The firm has a market cap of $2.63 billion, a PE ratio of -48.89 and a beta of 2.01. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. GeneDx has a one year low of $6.79 and a one year high of $115.60. The firm has a 50-day moving average of $79.05 and a 200 day moving average of $62.88.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group upped their target price on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday. Wells Fargo & Company upped their target price on shares of GeneDx from $34.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, October 30th. Craig Hallum upped their target price on shares of GeneDx from $70.00 to $95.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Finally, TD Cowen upped their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $72.33.

Insider Buying and Selling at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 1,657 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $78.48, for a total transaction of $130,041.36. Following the transaction, the chief executive officer now owns 3,937 shares in the company, valued at $308,975.76. This represents a 29.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Kevin Feeley sold 3,728 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $76.75, for a total transaction of $286,124.00. Following the transaction, the chief financial officer now owns 28,200 shares in the company, valued at approximately $2,164,350. The trade was a 11.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 127,584 shares of company stock valued at $11,336,520 in the last three months. 27.30% of the stock is currently owned by company insiders.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.